InvestorWire NewsRoom

Article

Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform
May 23, 2022

Aditxt Inc. (NASDAQ: ADTX) Planning Nationwide Rollout of its AditxtScore(TM) Immune Monitoring Platform

  • Aditxt recently entered a multi-year partnership with GRS for the promotion of its proprietary AditxtScore Immune Monitoring Platform
  • Aditxt plans to roll out the monitoring platform to medical offices, pharmacies, laboratories, and employers across the country, with promotion through nationwide television commercials 
  • AditxtScore(TM) monitors the current immune response not genetic sequencing 

Continuing research into COVID-19 is being done worldwide, with some researchers showing concern among the population of vaccinated individuals testing positive for the virus – including concerns about the durability of protection against highly contagious emerging strands. Researchers are still learning more about vaccinations against viruses and diseases in comparison to the body’s natural immune responses (https://ibn.fm/m2630).

“Following our comprehensive profiling of the effects of neutralizing antibodies, T cell immunity and non-neutralizing alternate antibody msabe found correlates of immunity in the context of both complete protection and mitigation of viral burden in breakthrough infection,” a major study’s co-author, Daniel Zhu, stated. “We also observed differences in the robustness of key immune response features across vaccine doses, insights that could help guide future vaccine design and boosting.” 

This is where immune system monitoring technologies such as the one developed by the biotech innovation company Aditxt (NASDAQ: ADTX), are already proving useful. Aditxt develops technologies focused on mapping and reprogramming the immune system. These immune mapping technologies were created to provide an individual and personalized immune profile. In the preclinical stage, these immune reprogramming technologies are being developed to retrain the immune system to induce tolerance to address rejection of transplanted organs, autoimmune diseases, and allergies.

Recently, Aditxt announced a multi-year partnership with GRS, an affiliate of Guthy-Renker LLC. The partnership will focus on building awareness and visibility among consumers and healthcare providers for the proprietary AditxtScore(TM) Immune Monitoring Platform. Aditxt plans to work closely with GRS to produce and air AditxtScore(TM) television and online commercials, helping to set the stage for an intended rollout in medical offices, pharmacies, laboratories, and employers nationwide (https://ibn.fm/ogSaT).

“AditxtScore(TM) is the right technology at the right time. Our first application, AditxtScore(TM) for COVID-19, delivers timely reports on vulnerability and immune status to SARS-CoV-2 and its known variants, giving consumers and their physicians the data they need to make informed health decisions for themselves and their families,” Aditxt co-founder and CEO Amro Albanna stated. 

Albanna added that the company’s AditxtScore immune monitoring center in Richmond, VA, which is fully operational and is designed to support increased demand for the company’s products and services, also voiced enthusiasm for working with GRS on the production of TV and online spots and marketing campaigns for AditxtScore: “Based on Guthy-Renker’s decades-long track record in direct marketing, GRS has proven that they understand what is required to help build a sustainable brand, and we believe this partnership is a great opportunity to introduce AditxtScore nationally.”

Boris Shimanovsky, President of GRS, also commented on the partnership, underlining that AditxtScore is designed to provide a more detailed profile of the immune system, allowing individuals to understand, manage, and monitor their immunity profiles. “We believe AditxtScore will fundamentally change what we know about immune health, and we’re excited to partner with the Aditxt team and help bring transparency and customer empowerment to an industry requiring both.”

Although still in its early stages, the immune repertoire sequencing market is forecasted to reach a value of $175 million by the end of 2027, registering a CAGR of 7.5% from 2020 to 2027. Growth in the industry is fueled by the advancements in next-generation sequencing, which have birthed the new technology in the form of immune repertoire sequencing, which is receiving widespread acceptance from the pharmacogenomics-based drug industry and the government (https://ibn.fm/pu1z8).

For more information, visit the company’s website at www.Aditxt.com.

NOTE TO INVESTORS: The latest news and updates relating to ADTX are available in the company’s newsroom at https://ibn.fm/ADTX

About InvestorWire

InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent. We offer UNLIMITED Words on all domestic releases. While other wire services may provide a basic review of your release, InvestorWire helps you put your best foot forward with complimentary Press Release Enhancement.

With our competitors, the work is done the second your release crosses the wire. Not with InvestorWire. We include follow-up coverage of every release by leveraging the ever-expanding audiences of the 50+ brands that make up the InvestorBrandNetwork.

Get more out of your next press release with InvestorWire. It’s unlike anything you’ve seen before.

For more information, please visit https://www.InvestorWire.com

Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer

InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]

InvestorWire is part of the InvestorBrandNetwork.

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).